Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis.
Ueda S, Saeki T, Osaki A, Yamane T, Kuji I.
Clin Cancer Res. 2017 Oct 1;23(19):5769-5778. doi: 10.1158/1078-0432.CCR-17-0874.Epub 2017 Jul 5. PMID: 28679773

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T.
Invest New Drugs. 2017 Jun 29. doi: 10.1007/s10637-017-0486-4. [Epub ahead of print]
PMID:28660549

Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast.
Shimada H, Hasebe T, Sugiyama M, Shibasaki S, Sugitani I, Ueda S, Gotoh Y, Yasuda M, Arai E, Osaki A, Saeki T.
Pathol Int. 2017 Jul;67(7):331-341. doi: 10.1111/pin.12550. Epub 2017 Jun 7.
PMID:28590017

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Sugitani I, Ueda S, Sakurai T, Shigekawa T, Hirokawa E, Shimada H, Takeuchi H, Matsuura K, Misumi M, Fujiuchi N, Takahashi T, Hasebe T, Osaki A, Saeki T.
Int J Clin Oncol. 2017 May 25. doi: 10.1007/s10147-017-1136-8. [Epub ahead of print]
PMID:28547525

Uncertainty of cosmetic evaluation after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.
Yoden E, Nose T, Otani Y, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Shikama N, Kumazaki Y, Takahashi T, Yoshida K, Kotsuma T, Masuda N, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M.
Jpn J Radiol. 2017 May 4. doi: 10.1007/s11604-017-0640-0. [Epub ahead of print]
PMID:28474300

Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.
Watanabe J, Ito Y, Saeki T, Masuda N, Takano T, Takao S, Nakagami K, Tsugawa K, Nakagawa S, Kanatani K, Nakayama T.
In Vivo. 2017 May-Jun;31(3):493-500.
PMID:28438884

Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y.
Cancer Sci. 2017 May;108(5):987-994. doi: 10.1111/cas.13221. Epub 2017 May 5.
PMID:28256066

Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan.
Int J Clin Oncol. 2017 Apr;22(2):405-412. doi: 10.1007/s10147-016-1069-7. Epub 2016 Dec 1.
PMID:27909835

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Mukai H, Saeki T, Aogi K, Naito Y, Matsubara N, Shigekawa T, Ueda S, Takashima S, Hara F, Yamashita T, Ohwada S, Sasaki Y.
Cancer Sci. 2016 Oct;107(10):1465-1470. doi: 10.1111/cas.13017. Epub 2016 Sep 15.
PMID:27452985

A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months.
Nose T, Otani Y, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Shikama N, Kumazaki Y, Takahashi T, Yoshida K, Kotsuma T, Masuda N, Yoden E, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M.
Breast Cancer. 2016 Nov;23(6):861-868. Epub 2015 Oct 14.
PMID:26467037

Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, Tanno J, Senbonmatsu T, Kasai T, Nishimura S.
Cardiol J. 2016;23(3):270-80. doi: 10.5603/CJ.a2016.0023. Epub 2016 May 13.
PMID:27173679

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.
Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, Osaki A.
Br J Cancer. 2016 May 24;114(11):1212-8. doi: 10.1038/bjc.2016.122. Epub 2016 May 3.
PMID:27140309

Symptomatic Radiation Pneumonitis After Accelerated Partial Breast Irradiation Using Three-dimensional Conformal Radiotherapy.
Shikama N, Kumazaki YU, Miyazawa K, Miyaura K, Kato S, Nakamura N, Kawamori J, Shimizuguchi T, Saito N, Saeki T.
Anticancer Res. 2016 May;36(5):2475-9.
PMID:27127160

[Choice of Adjuvant Chemotherapy Based on Breast Cancer Subtype].
Shimada H, Fujiuchi N, Saeki T.
Gan To Kagaku Ryoho. 2016 Feb;43(2):170-3. Japanese.
PMID:27067682

Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S, Yoshizawa N, Shigekawa T, Takeuchi H, Ogura H, Osaki A, Saeki T, Ueda Y, Yamane T, Kuji I, Sakahara H.
J Nucl Med. 2016 Aug;57(8):1189-95. doi: 10.2967/jnumed.115.167320. Epub 2016 Mar 3.
PMID:26940765

[Perinatal care and reproductive technique for patients with breast cancer].
Saeki T.
Gan To Kagaku Ryoho. 2015 Dec;42(13):2434. Japanese. No abstract available.
PMID:26841449

For choosing axillary treatment, and adjuvant hormonal treatment.
Toi M, Ohno S, Saeki T, Nakamura S, Thurlimann B.
Breast Cancer. 2016 Mar;23(2):167-9. doi: 10.1007/s12282-015-0662-3. Epub 2015 Dec 21. No abstract available.
PMID:26689708

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.
Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K.
Int J Clin Oncol. 2016 Feb;21(1):1-12. doi: 10.1007/s10147-015-0852-1. Epub 2015 Jun 17. PMID:26081252

miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H, Inoue S.
Sci Rep. 2015 Aug 10;5:13170. doi: 10.1038/srep13170.
PMID:26255816

A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: treatment planning and quality assurance.
Otani Y, Nose T, Dokiya T, Saeki T, Kumazaki Y, Asahi S, Tsukiyama I, Fukuda I, Sekine H, Shikama N, Takahashi T, Yoshida K, Kotsuma T, Masuda N, Yoden E, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M.
Radiat Oncol. 2015 Jun 4;10:126. doi: 10.1186/s13014-015-0430-8.
PMID:26040632

Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, Yamane T, Kuji I, Hasebe T, Osaki A.
Jpn J Clin Oncol. 2015 Jul;45(7):642-9. doi: 10.1093/jjco/hyv055. Epub 2015 May 19.
PMID:25989989

[Progress in second-line therapies for metastatic breast cancer].
Shigekawa T, Osaki A, Saeki T.
Gan To Kagaku Ryoho. 2015 Apr;42(4):408-15. Japanese.
PMID:25963688

Grading system for blood vessel tumor emboli of invasive ductal carcinoma of the breast.
Sugiyama M, Hasebe T, Shimada H, Takeuchi H, Shimizu K, Shimizu M, Yasuda M, Ueda S, Shigekawa T, Osaki A, Saeki T.
Hum Pathol. 2015 Jun;46(6):906-16. doi: 10.1016/j.humpath.2015.03.001. Epub 2015 Mar 18.
PMID:25890786

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T.
BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7.
PMID:25884795

[The survey for anti-emetic guideline by using questioner].
Saeki T, Tamura K, Aiba K, Aogi K, Iino K, Imamura C, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Matsuura K, Wada M, Akechi T, Kakudo Y, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Saito M, Ashikaga Y, Tanigawara Y, Hirata K, Ishioka C, Nishiyama M.
Gan To Kagaku Ryoho. 2015 Mar;42(3):305-11. Japanese.
PMID:25812498

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.
Cancer Sci. 2015 Jun;106(6):734-9. doi: 10.1111/cas.12658. Epub 2015 Apr 9.
PMID:25786335

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan.
Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15.
PMID:25681876

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K.
Support Care Cancer. 2015 Apr;23(4):1137-43. doi: 10.1007/s00520-014-2597-1. Epub 2015 Jan 10.
PMID:25576433

Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H, Saeki T, Shimada K, Naito Y, Matsubara N, Nakanishi T, Obaishi H, Namiki M, Sasaki Y.
Invest New Drugs. 2015 Feb;33(1):119-27. doi: 10.1007/s10637-014-0161-y. Epub 2014 Sep 23.
PMID:25242374

2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission.
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T.
Breast Cancer. 2015 Jan;22(1):1-4. doi: 10.1007/s12282-014-0550-2. Epub 2014 Jul 24. No abstract available.
PMID:25056934

[Breast and endocrine tumor – future prospective for sentinel lymph node biopsy].
Saeki T.
Gan To Kagaku Ryoho. 2014 Dec;41(13):2559. Japanese. No abstract available.
PMID:25668822

Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.
Ueda S, Kuji I, Shigekawa T, Takeuchi H, Sano H, Hirokawa E, Shimada H, Suzuki H, Oda M, Osaki A, Saeki T.
PLoS One. 2014 Jun 6;9(6):e98715. doi: 10.1371/journal.pone.0098715. eCollection 2014.
PMID:24905225

Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
Ueda S, Saeki T.
Breast Cancer. 2014 Nov;21(6):776-9. doi: 10.1007/s12282-014-0534-2. Epub 2014 May 4.
PMID:24795075

Clinicopathological and prognostic impact of imaging of breast cancer angiogenesis and hypoxia using diffuse optical spectroscopy.
Nakamiya N, Ueda S, Shigekawa T, Takeuchi H, Sano H, Hirokawa E, Shimada H, Suzuki H, Oda M, Osaki A, Saeki T.
Cancer Sci. 2014 Jul;105(7):833-9. doi: 10.1111/cas.12432. Epub 2014 Jun 27.
PMID:24766271

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.
PMID:24742606

[Breast and endocrine tumor].
Saeki T.
Gan To Kagaku Ryoho. 2013 Dec;40(13):2499. Japanese. No abstract available.
PMID:24422235

[Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice].
Saeki T, Tokuda Y, Takigawa N, Tsurutani J.
Gan To Kagaku Ryoho. 2013 Oct;40(10):1365-76. Japanese. No abstract available.
PMID:24312985

Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast.
Ueda S, Nakamiya N, Matsuura K, Shigekawa T, Sano H, Hirokawa E, Shimada H, Suzuki H, Oda M, Yamashita Y, Kishino O, Kuji I, Osaki A, Saeki T.
BMC Cancer. 2013 Oct 31;13:514. doi: 10.1186/1471-2407-13-514.
PMID:24176197

Genomic profiling shows increased glucose metabolism in luminal B breast cancer.
Ueda S, Saeki T, Takeuchi H, Shigekawa T, Matsuura K, Nakamiya N, Sano H, Shimada H, Hirokawa E, Osaki A.
J Breast Cancer. 2013 Sep;16(3):342-4. doi: 10.4048/jbc.2013.16.3.342. Epub 2013 Sep 30.
PMID:24155765

Association of positive EBAG9 immunoreactivity with unfavorable prognosis in breast cancer patients treated with tamoxifen.
Ijichi N, Shigekawa T, Ikeda K, Miyazaki T, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.
Clin Breast Cancer. 2013 Dec;13(6):465-70. doi: 10.1016/j.clbc.2013.08.015. Epub 2013 Oct 8.
PMID:24119785

The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Sagara Y, Sato K, Fukuma E, Higaki K, Mizutani M, Osaki A, Takano T, Tokuda Y, Ohno S, Masuda N, Suzuki M, Saeki T.
Jpn J Clin Oncol. 2013 Sep;43(9):865-73. doi: 10.1093/jjco/hyt091. Epub 2013 Jul 14.
PMID:23858037

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T, Noguchi S.
Breast Cancer Res Treat. 2013 Jun;139(2):441-51. doi: 10.1007/s10549-013-2573-3. Epub 2013 May 30.
PMID:23715630

Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.
Sekine I, Segawa Y, Kubota K, Saeki T.
Cancer Sci. 2013 Jun;104(6):711-7. doi: 10.1111/cas.12146. Epub 2013 Apr 16.
PMID:23480814

[Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].
Shigekawa T, Takeuchi H, Misumi M, Nakamiya N, Sugiyama M, Sugitani I, Fujiuchi N, Osaki A, Saeki T.
Gan To Kagaku Ryoho. 2013 Feb;40(2):225-7. Japanese.
PMID:23411960

Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
Shionome Y, Yan L, Liu S, Saeki T, Ouchi T.
PLoS One. 2013;8(1):e55457. doi: 10.1371/journal.pone.0055457. Epub 2013 Jan 31.
PMID:23383195

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T.
Int J Clin Oncol. 2013 Aug;18(4):598-606. doi: 10.1007/s10147-012-0437-1. Epub 2012 Jul 26.
PMID:22833344

(1)H MR spectroscopy with external reference solution at 1.5 T for differentiating malignant and benign breast lesions: comparison using qualitative and quantitative approaches.
Mizukoshi W, Kozawa E, Inoue K, Saito N, Nishi N, Saeki T, Kimura F.
Eur Radiol. 2013 Jan;23(1):75-83. doi: 10.1007/s00330-012-2555-6. Epub 2012 Jul 10.
PMID:22777619
https://www.ncbi.nlm.nih.gov/pubmed/22676245

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y.
Int J Clin Oncol. 2013 Aug;18(4):590-7. doi: 10.1007/s10147-012-0421-9. Epub 2012 May 15.
PMID:22585426